Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Glecaprevir is a Hepatitis C NS3/4A protease inhibitor used to treat Hepatitis C. In combination with DB13878, glecaprevir is a useful therapy for patients who experienced therapeutic failure from other NS3/4A protease inhibitors.
- Mechanism
- Curator reviewed · 3 references
Glecaprevir is an inhibitor of the HCV NS3/4A protease, which is a viral enzyme necessary for the proteolytic cleavage of the HCV encoded polyprotein into mature forms of the NS3, NS4A, NS4B, NS5A, and NS5B proteins. These multifunctional proteins, including NS3, are essential for viral replication. The N-terminal of NS3 protein confers serine protease activity, whileThe C-terminus of NS3 encodes a DExH/D-box RNA helicase which hydyolyzes NTP as an energy source to unwind double-stranded RNA in a 3′ to 5′ direction during replication of viral genomic RNA. NS4A is a cofactor for NS3 that directs the localization of NS3 and modulates its enzymatic activities. Glecaprevir disrupts the intracellular processes of the viral life cycle through inhibiting the NS3/4A protease activity of cleaving downstream junctions of HCV polypeptide and proteolytic processing of mature structural proteins.
- Primary indication
- Indicated for the treatment of adult patients with acute and chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A).Curator reviewed · 27 structured indications
- Formula / weight
- C38H46F4N6O9S · 838.87 g/mol (avg)
- First approval
- Canada, 2017 · United States, 2017 · European Union, 2020
- Code names
- A-1282576 · A-1282576.0 · ABT-493
- Brand names
- Maviret
- Mavyret
Resolves to
MLSQGNCUYAMAHD-ITNVBOSISA-NSMILES[H][C@@]12CN(C(=O)[C@@]([H])(NC(=O)O[C@]3([H])CCC[C@@]3([H])OC\C=C\C(F)(F)C3=NC4=C(C=CC=C4)N=C3O1)C(C)(C)C)[C@@]([H])(C2)C(=O)N[C@@]1(C[C@H]1C(F)F)C(=O)NS(=O)(=O)C1(C)CC1What you can answer from here — as of September 23, 2026
Which drugs share a target with Glecaprevir, and which of those have an active Phase 3 trial?